Add BrightSurf on Google Email

Science News for October 18, 2009


What's the clonality status and allelotype of focal nodular hyperplasia?

Researchers analyzed 12 focal nodular hyperplasia (FNH) lesions and found polyclonal nature with no loss of heterozygosity in most cases, contrasting with 40% monoclonality in altered hepatocytes. This study provides an approach for differential diagnosis and may lead to further understanding of early human hepatocarcinogenesis.

SourceWorld Journal of Gastroenterology·JournalWorld Journal of Gastroenterology·DateOct 18, 2009

Metals could forge new cancer drug

A new class of compounds containing Ruthenium and Osmium has been found to be highly effective in killing ovarian and colon cancer cells, even those resistant to Cisplatin. The discovery is a significant step forward in the field of medicinal chemistry.

SourceUniversity of Warwick·JournalJournal of Medicinal Chemistry·DateOct 18, 2009

Time in a bottle: Scientists watch evolution unfold

A Michigan State University experiment has watched the emergence of natural selection over 40,000 generations, providing insights into genome evolution and adaptation. The study's findings have implications for biotechnology and cancer research, revealing complex relationships between genetic mutations and environmental pressures.

SourceMichigan State University·JournalNature·DateOct 18, 2009

APP -- Good, bad or both?

Research at Georgetown University Medical Center found that APP plays a critical role in brain development, connection of synapses, and dendritic spine development. Overproducing APP can lead to Abeta plaques and cognitive decline, highlighting the importance of maintaining balance in APP protein expression.